3 results on '"Yi, M"'
Search Results
2. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.
- Author
-
Yamazaki N, Isei T, Kiyohara Y, Koga H, Kojima T, Takenouchi T, Yokota K, Namikawa K, Yi M, Keegan A, and Fukushima S
- Subjects
- Adult, Female, Herpesvirus 1, Human, Humans, Japan, Male, Biological Products adverse effects, Melanoma drug therapy, Melanoma pathology, Oncolytic Virotherapy adverse effects, Skin Neoplasms drug therapy, Skin Neoplasms pathology
- Abstract
Talimogene laherparepvec (T-VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open-label, dose de-escalation study evaluated the safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV melanoma. Eligible adult patients had histologically confirmed stage IIIB-IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had ≥1 injectable lesion, serum lactate dehydrogenase ≤1.5x upper limit of normal, ECOG performance status of 0 or 1, and adequate hematologic, hepatic, and renal function. T-VEC was injected intralesionally (first dose, ≤4.0 ml of 10
6 PFU/ml; after 3 weeks and then every 2 weeks thereafter, ≤4.0 ml of 108 PFU/ml). Primary endpoints were dose-limiting toxicities (DLTs) and durable response rate (DRR). Of 18 enrolled patients (72.2% female), 16 had received ≥1 prior line of therapy. Ten patients discontinued T-VEC due to disease progression. Median (range) follow-up was 20.0 (4-37) months. No DLTs were observed; 17 (94.4%) patients had treatment-emergent adverse events (AEs). Fourteen (77.8%) patients had treatment-related AEs; the most frequent were pyrexia (44.4%), malaise (16.7%), chills, decreased appetite, pruritus, and skin ulcer (11.1% each). The primary efficacy endpoint was met: 2 (11.1%) patients had a durable partial response ≥6 months. The DRR was consistent with that observed in a phase III trial of T-VEC in non-Asian patients. The safety profile was consistent with the patients' underlying disease and the known safety profile of T-VEC., (© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2022
- Full Text
- View/download PDF
3. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
- Author
-
Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, and Kaneko S
- Subjects
- Adult, Aged, Base Sequence, Cell Line, Tumor, Drug Therapy, Combination, Female, Forkhead Box Protein O3, Forkhead Transcription Factors genetics, Genotype, Hepacivirus drug effects, Hepacivirus genetics, Hepacivirus growth & development, Hepatitis C, Chronic complications, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic metabolism, Humans, Interferon alpha-2, Interferons, Interleukins genetics, Interleukins metabolism, Japan, Liver metabolism, Liver virology, Liver Cirrhosis metabolism, Liver Cirrhosis virology, Male, Malnutrition virology, Mechanistic Target of Rapamycin Complex 1, Middle Aged, Molecular Sequence Data, Multiprotein Complexes, Odds Ratio, Polymorphism, Genetic, Proteins genetics, Proteins metabolism, RNA Interference, RNA, Viral blood, Recombinant Proteins, Regression Analysis, Ribavirin therapeutic use, Severity of Illness Index, Suppressor of Cytokine Signaling 3 Protein, Suppressor of Cytokine Signaling Proteins genetics, Suppressor of Cytokine Signaling Proteins metabolism, TOR Serine-Threonine Kinases genetics, Transaminases metabolism, Transfection, Treatment Outcome, Viral Load, Virus Replication drug effects, Antiviral Agents therapeutic use, Forkhead Transcription Factors metabolism, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Liver drug effects, Malnutrition metabolism, Nutritional Status, Polyethylene Glycols therapeutic use, Signal Transduction drug effects, TOR Serine-Threonine Kinases metabolism
- Abstract
Background & Aims: Patients with advanced chronic hepatitis C (CH-C) often are malnourished, but the effects of malnutrition on interferon (IFN) signaling and response to treatment have not been determined. We assessed the importance of the nutritional state of the liver on IFN signaling and treatment response., Methods: We studied data from 168 patients with CH-C who were treated with the combination of pegylated-IFN and ribavirin. Plasma concentrations of amino acids were measured by mass spectrometry. Liver gene expression profiles were obtained from 91 patients. Huh-7 cells were used to evaluate the IFN signaling pathway, mammalian target of rapamycin complex 1 (mTORC1), and forkhead box O (FoxO). Antiviral signaling induced by branched-chain amino acids (BCAAs) was determined using the in vitro hepatitis C virus replication system., Results: Multivariate logistic regression analysis showed that Fischer's ratio was associated significantly with nonresponders, independent of interleukin-28B polymorphisms or the histologic stage of the liver. Fischer's ratio was correlated inversely with the expression of BCAA transaminase 1, and was affected by hepatic mTORC1 signaling. IFN stimulation was impaired substantially in Huh-7 cells grown in medium that was low in amino acid concentration, through repressed mTORC1 signaling, and increased Socs3 expression, which was regulated by Foxo3a. BCAA could restore impaired IFN signaling and inhibit hepatitis C virus replication under conditions of malnutrition., Conclusions: Malnutrition impaired IFN signaling by inhibiting mTORC1 and activating Socs3 signaling through Foxo3a. Increasing BCAAs to up-regulate IFN signaling might be used as a new therapeutic approach for patients with advanced CH-C., (Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.